- Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
This study looks at a new treatment called pembrolizumab, combined with standard chemotherapy, for adults recently diagnosed with classical Hodgkin lymphoma. Researchers want to see how many patients go into complete remission at the end of the treatment plan.
For: Classical Hodgkin LymphomaFrance · Poland · Spain - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Metro-PD1-1708: a phase I/II trial evaluating anti-PD1 (Nivolumab) in combination with metronomic chemotherapy in children and teenagers with refractory /relapsing solid tumors
This study looks at new ways to treat children and teenagers with solid cancers that have come back or haven't responded to usual treatments. It combines a new immune-boosting drug (Nivolumab) with milder chemotherapy to see if it's safe and effective.
For: Progressive or refractory paediatric solid tumorFrance - Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia